FY2025 Earnings Estimate for TECX Issued By Lifesci Capital

Tectonic Therapeutic, Inc. (NASDAQ:TECX) – Investment analysts at Lifesci Capital issued their FY2025 earnings estimates for shares of Tectonic Therapeutic in a research note issued on Thursday, February 5th. Lifesci Capital analyst G. Maini anticipates that the company will post earnings of ($4.72) per share for the year. Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Tectonic Therapeutic’s current full-year earnings is ($8.31) per share. Lifesci Capital also issued estimates for Tectonic Therapeutic’s Q4 2025 earnings at ($1.21) EPS.

Other equities analysts have also recently issued reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tectonic Therapeutic in a report on Thursday, January 22nd. Wells Fargo & Company started coverage on Tectonic Therapeutic in a research report on Monday, October 20th. They issued an “overweight” rating and a $101.00 target price for the company. Finally, Truist Financial cut their target price on Tectonic Therapeutic from $64.00 to $60.00 and set a “buy” rating for the company in a research note on Thursday, January 8th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $81.50.

Tectonic Therapeutic Stock Down 15.2%

TECX opened at $21.05 on Monday. The business’s fifty day simple moving average is $20.48 and its 200 day simple moving average is $19.62. Tectonic Therapeutic has a 52 week low of $13.70 and a 52 week high of $36.11. The stock has a market cap of $394.06 million, a PE ratio of -5.45 and a beta of 3.71.

Institutional Investors Weigh In On Tectonic Therapeutic

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. AlphaQuest LLC grew its position in Tectonic Therapeutic by 919.4% during the 2nd quarter. AlphaQuest LLC now owns 2,365 shares of the company’s stock worth $47,000 after acquiring an additional 2,133 shares during the last quarter. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Tectonic Therapeutic during the second quarter valued at approximately $52,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Tectonic Therapeutic by 26.7% during the second quarter. China Universal Asset Management Co. Ltd. now owns 3,750 shares of the company’s stock valued at $75,000 after purchasing an additional 791 shares during the period. Caitong International Asset Management Co. Ltd grew its holdings in shares of Tectonic Therapeutic by 451.6% in the third quarter. Caitong International Asset Management Co. Ltd now owns 3,966 shares of the company’s stock worth $62,000 after purchasing an additional 3,247 shares during the last quarter. Finally, Virtus Investment Advisers LLC increased its stake in shares of Tectonic Therapeutic by 18.3% in the second quarter. Virtus Investment Advisers LLC now owns 4,190 shares of the company’s stock worth $83,000 after buying an additional 649 shares during the period. Institutional investors own 62.63% of the company’s stock.

About Tectonic Therapeutic

Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.